Crestor (rosuvastatin calcium) is a newer cholesterol-lowering medication that belongs to a popular class of drugs known as statins. In 2003 the FDA approved Crestor to help reduce the overall level of “bad” cholesterol in the blood stream, which is an especially effective treatment when accompanied by regular exercise and a low-cholesterol diet. Manufactured by AstraZeneca, Crestor has also been marketed as a “super statin” and is approved for a complementary use: increasing the body’s levels of high density lipoprotein (HDL), also known as “good” cholesterol.
Within months of Crestor’s release to the market, users taking approved 80mg dosages of the prescription drug started reporting serious side effects, including muscle damage, kidney failure and rhabdomyolysis, the rapid breakdown of skeletal muscle and dangerous release of the protein myoglobin into the bloodstream.
Consumer groups are now asking for a full recall of Crestor, citing a previously known link to rhabdomyolysis in Crestor’s pre-release studies and established connections between earlier statin drugs and lethal side effects. Another strong statin Baycol was already removed from the market in 2001 following a proven link between the drug and the onset of rhabdomylosis, which can lead to kidney failure and death.
While AstraZeneca has withdrawn Crestor’s potentially harmful 80mg dosage from the market, consumer reports continue to link this drug to adverse side effects. If you need more information about lawsuits pending against the maker of Crestor, please give us call. We are actively assisting former Crestor users in litigation against a manufacturer that may have knowingly allowed a super statin to remain unchecked for too long on the U.S. market.